Background and objectives
A few studies have found that low scores on self-rated health and quality of life measures are associated with following worsening disability in multiple sclerosis (MS). We wanted to estimate the association between self-rated quality of life scores among patients with clinically isolated syndrome (CIS) and the risk of subsequent conversion to definite MS.
One hundred sixty-two patients from the GERONIMUS cohort with a symptom or sign suggestive of MS and without a definite diagnosis of MS at the time of inclusion were asked to evaluate their health-related quality of life according to MSQoL-54 scale. They were clinically assessed and mood and depression scales were applied. The association between the scores of these scales and the risk of converting to definite MS during a 5-year follow-up was estimated using the Cox- proportional hazard regression model.
Quality of life at examination was significantly lower compared to those of an age- and sex-adjusted general Italian population. During the follow-up, 116 patients (72%) converted to definite MS. No significant predictive effects were found for the summary scales of MSQol-54 or other scales. The estimates did not change after adjusting for age, sex, BMI, education, MRI findings, Expanded Disability Status Scale (EDSS) score, and treatment at time of examination.
Persons with CIS in this cohort reported reduced self-rated quality of life compared to the general population, but variation in these scores was not associated with subsequent conversion from CIS to clinical definite MS.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Vukusic S, Confavreux C (2007) Natural history of multiple sclerosis: risk factors and prognostic indicators. Curr Opin Neurol 20(3):269–274. https://doi.org/10.1097/WCO.0b013e32812583ad
Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis. An expanded disability status scale (EDSS). Neurology 33(11):1444–1452. https://doi.org/10.1212/wnl.33.11.1444
Nortvedt MW, Riise T, Myhr KM, Nyland HI (2000) Quality of life as a predictor for change in disability in MS. Neurology 55(1):51–54
Visschedijk MA, Uitdehaag BM, Klein M, van der Ploeg E, Collette EH, Vleugels L, Pfennings LE, Hoogervorst EL, van der Ploeg HM, Polman CH (2004) Value of health-related quality of life to predict disability course in multiple sclerosis. Neurology 63(11):2046–2050
Guarnaccia JB, Aslan M, O'Connor TZ, Hope M, Kazis L, Kashner CM, Booss J (2006) Quality of life for veterans with multiple sclerosis on disease-modifying agents: relationship to disability. J Rehabil Res Dev 43(1):35–44
Drulovic J, Riise T, Nortvedt M, Pekmezovic T, Manigoda M (2008) Self-rated physical health predicts change in disability in multiple sclerosis. Mult Scler 14(7):999–1002. https://doi.org/10.1177/1352458508088917
Benito-Leon J, Mitchell AJ, Rivera-Navarro J, Morales-Gonzalez JM (2013) Impaired health-related quality of life predicts progression of disability in multiple sclerosis. Eur J Neurol 20(1):79–86. https://doi.org/10.1111/j.1468-1331.2012.03792.x
Baumstarck K, Pelletier J, Butzkueven H, Fernandez O, Flachenecker P, Idiman E, Stecchi S, Boucekine M, Auquier P, MusiQo Lsg (2013) Health-related quality of life as an independent predictor of long-term disability for patients with relapsing-remitting multiple sclerosis. Eur J Neurol 20(6):907–914, e978-909. https://doi.org/10.1111/ene.12087
Tepavcevic DK, Pekmezovic T, Stojsavljevic N, Kostic J, Basuroski ID, Mesaros S, Drulovic J (2013) Predictive value of health-related quality of life in progression of disability and depression in persons with multiple sclerosis: a 3-year study. Acta Neurol Belg 113(4):403–409. https://doi.org/10.1007/s13760-013-0191-9
Hadgkiss EJ, Jelinek GA, Taylor KL, Marck CH, van der Meer DM, Pereira NG, Weiland TJ (2015) Engagement in a program promoting lifestyle modification is associated with better patient-reported outcomes for people with MS. Neurol Sci 36(6):845–852. https://doi.org/10.1007/s10072-015-2089-1
D’Alessandro R, Vignatelli L, Lugaresi A, Baldin E, Granella F, Tola MR, Malagu S, Motti L, Neri W, Galeotti M, Santangelo M, Fiorani L, Montanari E, Scandellari C, Benedetti MD, Leone M (2013) Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study. J Neurol 260(6):1583–1593. https://doi.org/10.1007/s00415-013-6838-x
Mattarozzi K, Vignatelli L, Baldin E, Lugaresi A, Pietrolongo E, Tola MR, Motti L, Neri W, Calzoni S, Granella F, Galeotti M, Santangelo M, Malagu S, Fiorani L, Guareschi A, Scandellari C, D’Alessandro R (2012) Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: a prospective study. Int J Clin Pract 66(5):504–514. https://doi.org/10.1111/j.1742-1241.2012.02912.x
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121–127
Solari A, Filippini G, Mendozzi L, Ghezzi A, Cifani S, Barbieri E, Baldini S, Salmaggi A, Mantia LL, Farinotti M, Caputo D, Mosconi P (1999) Validation of Italian multiple sclerosis quality of life 54 questionnaire. J Neurol Neurosurg Psychiatry 67(2):158–162
Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW (1995) A health-related quality of life measure for multiple sclerosis. Qual Life Res Int J Qual Life Asp Treat Care Rehab 4(3):187–206
Ware JE (1993) SF-36 health survey manual and interpretation guide. The health institute, New England Medical Center, Boston
Apolone G, Mosconi P (1998) The Italian SF-36 health survey: translation, validation and norming. J Clin Epidemiol 51(11):1025–1036
McNair DM, Lorr M, Droppleman LF (1992) Revised manual for the Profile of Mood States. Educational and industrial testing service. Educational and Industrial Testing Services, San Diego
Solari A, Motta A, Mendozzi L, Aridon P, Bergamaschi R, Ghezzi A, Mancardi GL, Milanese C, Montanari E, Pucci E (2004) Italian version of the Chicago multiscale depression inventory: translation, adaptation and testing in people with multiple sclerosis. Neurol Sci 24(6):375–383. https://doi.org/10.1007/s10072-003-0192-1
Mitchell AJ, Benito-León J, González J-MM, Rivera-Navarro J (2005) Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol 4(9):556–566. https://doi.org/10.1016/S1474-4422(05)70166-6
Di Legge S, Piattella MC, Pozzilli C, Pantano P, Caramia F, Pestalozza IF, Paolillo A, Lenzi GL (2003) Longitudinal evaluation of depression and anxiety in patients with clinically isolated syndrome at high risk of developing early multiple sclerosis. Mult Scler 9(3):302–306. https://doi.org/10.1191/1352458503ms921oa
The authors thank all patients and clinical researchers who contributed to the G.E.Ro.N.I.Mu.S study. We are indebted to Eleonora Romagnoli, Silvia Canala, and the YGHEA staff for their precious technical assistance. Members of the G.E.Ro.N.I.Mu.S. study group are as follows: Marianna Pattini, MD (Centro Sclerosi Multipla, U.O di Neurologia, Ospedale Civile –Localita’ Vaio, Site investigators); Erica Curti, MD, Elena Tsantes, MD (Centro Sclerosi Multipla Dipartimento di Neuroscienze,Universita` di Parma, site investigator); Enrico Montanari, MD; Angelica Guaresci,MD (Centro Sclerosi Multipla, Ospedale di Fidenza, Parma, site investigator); Concetta Feo (U.O.S Neurofisiologia, U.O. Neurologia, Ospedale Santa Maria Nuova, Reggio Emilia, site investigator); Sergio Stecchi, MD; Lucia La Mola; Renzo Balugani (UO Riabilitazione-Sclerosi Multipla, IRCCS Istituto delle Scienze Neurologiche, Bologna, site investigators); Fabio Pizza, MD (Dipartimento di Scienze Neurologiche, Universita’ di Bologna, site investigator); Laura Delaj, MD; Silvia De Pasqua, MD; Rita Rinaldi, MD (U.O Neurologia, Dipartimento Neuro-Senso-Motorio, Policlinico S.Orsola-Malpighi, Bologna, site investigators); Eleonora Baldi, MD, Luisa Caniatti, MD, Paola Milani, Psychologist (Dipartimento di Neuroscienze,Azienda Ospedaliero Universitaria S. Anna, Ferrara, site investigators and psychologic testing); Vittoria Mussuto, MD; Monica Manzoni, Psycologist (U.O. Neurologia, Ospedale Santa Maria della Scaletta, Imola, site investigators); Mario Casmiro, MD; Claudia Guerrini (Ospedale per gli Infermi,AUSL Ravenna, Faenza, site investigators); Laura Mambelli (U.O. di Neurologia, Presidio Ospedaliero G.B. Morgagni-L. Pierantoni, Forlı`, site investigator); Paola Naldi, MD; Laura Collimedaglia, Domizia Vecchio (SCDU Neurologia, A.O.U. “Maggiore della Carita`”, Novara, site investigators); Erika Pietrolongo, PhD; Valeria Di Tommaso, MD; Giovanna DeLuca, MD; Daniela Travaglini, MD (Centro Sclerosi Multipla, Clinica Neurologica, Dipartimento di Neuroscienze e Imaging, Universita` “G. d’Annunzio”, Chieti, site investigators and psychological testing); Maria Donata Benedetti, MD; Francesca Rossi, MD (Neurologia B - Policlinico Borgo Roma AOUI Verona, site investigators); Marco Pastore Trossello, MD; Luca Faccioli, MD; Luca Spinardi, MD (SSD Neuroradiologia, AOSP, Bologna, MRI review).
This study was supported with an unconditional grant by Biogen Idec and by the Department of Neurological Sciences of the University of Bologna. None of the authors received fees for the participation to the study.
Conflicts of interest
A. Gajofatto reports personal fees and grants from MERCK, non-financial support from NOVARTIS. F. Granella reports grants, personal fees, and non-financial support from Biogen, personal fees and non-financial support from Sanofi Genzyme, Novartis, Merck, and non-financial support from Almirall. M. Leone reports grants from TEVA. A. Lugaresi reports grants and personal fees from Bayer, Biogen, Merck, Novartis, Sanofi- Genzyme, Teva, and Almirall. S. Malagù reports non-financial support from Biogen, Sanofy-Aventis, personal fees and non-financial support from Merck-Serono, personal fees from Bayer, Novartis. E. Baldin, R. D’Alessandro, K. Mattarozzi, L. Motti, W. Neri, I. Pesci, T. Riise, M. Santangelo, C. Scandellari, M.R. Tola, L. Vignatelli, and C. Zenesini have no conflicts of interest to disclose.
About this article
Cite this article
Baldin, E., Riise, T., Mattarozzi, K. et al. Health-related quality of life in clinically isolated syndrome and risk of conversion to multiple sclerosis. Neurol Sci 40, 75–80 (2019). https://doi.org/10.1007/s10072-018-3582-0
- Clinically isolated syndrome (CIS)
- Multiple sclerosis
- Prognostic factors
- Prospective study
- Quality of life
- Self-rated health